RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

A few thoughts:
1) Reversal/regeneration of neurodegeneration would be an unexpected boon, but in an aged population, just slowing progression would be terrific, and has yet to be accomplished.
2) Servier does not appear to have started Phase II. For symptomatic treatments, they've gone as short as four weeks in the past, for disease-slowing, six months.
3) If either UCI/Lynch or Cortex had seen evidence of low-impacts producing enough BDNF to be disease-modifying, they would have been all over it....they haven't pursued the tough nut of high-impacts for the exercise...
4) There is a world of difference between the safety window for Parkinson's compared to ADHD. Look at some of the programs currently in Phase IIa or IIb testing, using neurosurgically implanted cells and/or viral vector gene therapy: Ceregene, NeuroNova, Neurologix.
5) I'm still hoping for nonhuman primate PD data in the next couple of months, if distinctly positive, perhaps turning into MJFF support for human testing (they've paid for some of Ceregene's clinical testing for CERE-120).
6) Big Pharma isn't generally interested in licensing platforms, unless it's a discovery stage platform they can a junior partner develop. They want a lead compound and a backup or two....

NeuroInvestment